Herrera-Gómez, R.G.; Grecea, M.; Gallois, C.; Boige, V.; Pautier, P.; Pistilli, B.; Planchard, D.; Malka, D.; Ducreux, M.; Mir, O.
Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease. Cancers 2022, 14, 2914.
https://doi.org/10.3390/cancers14122914
AMA Style
Herrera-Gómez RG, Grecea M, Gallois C, Boige V, Pautier P, Pistilli B, Planchard D, Malka D, Ducreux M, Mir O.
Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease. Cancers. 2022; 14(12):2914.
https://doi.org/10.3390/cancers14122914
Chicago/Turabian Style
Herrera-Gómez, Ruth Gabriela, Miruna Grecea, Claire Gallois, Valérie Boige, Patricia Pautier, Barbara Pistilli, David Planchard, David Malka, Michel Ducreux, and Olivier Mir.
2022. "Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease" Cancers 14, no. 12: 2914.
https://doi.org/10.3390/cancers14122914
APA Style
Herrera-Gómez, R. G., Grecea, M., Gallois, C., Boige, V., Pautier, P., Pistilli, B., Planchard, D., Malka, D., Ducreux, M., & Mir, O.
(2022). Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease. Cancers, 14(12), 2914.
https://doi.org/10.3390/cancers14122914
